About Steve Gullans
Steve Gullans is co-founder and co-chair of Thynk, which makes a brain-wave-controlled video game that trains focus, and he was its CEO from its founding in 2023. He co-founded the venture firm Excel Venture Management in 2008, was a managing director there for ten years and remains a special advisor. He sits on the boards of Orionis Biosciences, Navigation Sciences and Alexis Bio, and on the business advisory board of InnoCom.
He was president and CEO of Gemphire Therapeutics from 2018 to 2019, after joining its board in 2016, and he was a director of iSpecimen from 2020 to 2024. Earlier he co-founded RxGen and ran it from 2004 to 2008, and he was chief scientific officer of US Genomics from 2002 to 2004. Before that he spent almost 20 years on the faculty of Harvard Medical School and Brigham and Women's Hospital. His past board seats include Tetraphase Pharmaceuticals, Cleveland HeartLab, N-of-One, Molecular Templates, BioTrove and Biocius Life Sciences.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Steve Gullans in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Steve Gullans works with at each company, as listed on that company's latest Form D.
Steve Gullans in the News
Sources
- SECThynk, Inc. Form D, filed Aug 18, 2026
- SEC filingiSpecimen proxy statement, June 2024 (director biography)
- SEC filingiSpecimen prospectus, May 2021 (director biography)
- SEC filingiSpecimen S-1/A, October 2025 (director dates)
- SEC filingGemphire Therapeutics S-1/A, June 2016 (director biography)
- SEC filingGemphire Therapeutics S-1/A, August 2016 (signed as board member)
- SEC filingTetraphase Pharmaceuticals S-1/A, March 2013 (director biography)
- Other company siteBusiness advisory board page on innocombio.com